HPV Vaccine Appears Safe in Early Pregnancy
|
By HospiMedica International staff writers Posted on 14 Apr 2017 |
A new study suggests that vaccination against human papillomavirus (HPV) during pregnancy does not increase the risk of maternal or fetal complications.
Researchers at the Danish Statens Serum Institut conducted a retrospective study of all women in Denmark who had a pregnancy that ended between October 1, 2006, and November 30, 2013. Using nationwide registers, the researchers linked data on quadrivalent HPV vaccination, adverse pregnancy outcomes, and potential confounders. Vaccinated women were matched on a 1:4 ratio with women who were not. Study outcomes included a range of gestational and newborn factors.
The results revealed 65 birth defects in vaccine-exposed pregnancies, compared to 220 in unexposed pregnancies; 20 spontaneous abortions with vaccine exposure versus 131 without; 116 preterm births versus 407; 76 cases of low birth weight versus 277; 171 cases of small size for gestational age versus 783; and two stillbirths versus four. Upon analysis, exposure to HPV vaccine was not associated with significantly higher risks for major birth defect, spontaneous abortion, preterm birth, low birth weight, small size for gestational age, or stillbirth. The study was published on March 30, 2017, in the New England Journal of Medicine (NEJM).
“Our results are consistent with other evidence that does not indicate that the vaccination of pregnant women with inactivated virus, bacterial, or toxoid vaccines generally confers a higher risk of adverse pregnancy outcomes than no such vaccination,” concluded lead author Nikolai Scheller, MD, and colleagues. “Our results also confirm and considerably expand on results from previous studies of the quadrivalent HPV vaccine.”
Introduced in 2006, the quadrivalent HPV vaccine covers the four viral strains most closely associated with gynecologic cancer (HPV-6, 11, 16, and 18). HPV types 6 and 11 also cause genital warts. As of 2014, 58 countries include HPV in their routine vaccinations for all girls around the ages of 9-13, and some countries vaccinate boys as well; the vaccines provide protection for at least eight years. Denmark also vaccinates women up to 26 years of age, and as a result some women are inadvertently exposed to HPV vaccination during early pregnancy.
Researchers at the Danish Statens Serum Institut conducted a retrospective study of all women in Denmark who had a pregnancy that ended between October 1, 2006, and November 30, 2013. Using nationwide registers, the researchers linked data on quadrivalent HPV vaccination, adverse pregnancy outcomes, and potential confounders. Vaccinated women were matched on a 1:4 ratio with women who were not. Study outcomes included a range of gestational and newborn factors.
The results revealed 65 birth defects in vaccine-exposed pregnancies, compared to 220 in unexposed pregnancies; 20 spontaneous abortions with vaccine exposure versus 131 without; 116 preterm births versus 407; 76 cases of low birth weight versus 277; 171 cases of small size for gestational age versus 783; and two stillbirths versus four. Upon analysis, exposure to HPV vaccine was not associated with significantly higher risks for major birth defect, spontaneous abortion, preterm birth, low birth weight, small size for gestational age, or stillbirth. The study was published on March 30, 2017, in the New England Journal of Medicine (NEJM).
“Our results are consistent with other evidence that does not indicate that the vaccination of pregnant women with inactivated virus, bacterial, or toxoid vaccines generally confers a higher risk of adverse pregnancy outcomes than no such vaccination,” concluded lead author Nikolai Scheller, MD, and colleagues. “Our results also confirm and considerably expand on results from previous studies of the quadrivalent HPV vaccine.”
Introduced in 2006, the quadrivalent HPV vaccine covers the four viral strains most closely associated with gynecologic cancer (HPV-6, 11, 16, and 18). HPV types 6 and 11 also cause genital warts. As of 2014, 58 countries include HPV in their routine vaccinations for all girls around the ages of 9-13, and some countries vaccinate boys as well; the vaccines provide protection for at least eight years. Denmark also vaccinates women up to 26 years of age, and as a result some women are inadvertently exposed to HPV vaccination during early pregnancy.
Latest Patient Care News
- AI Avatar Doctor Improves Patient Understanding Before Radiotherapy
- Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
- Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
- VR Training Tool Combats Contamination of Portable Medical Equipment
- Portable Biosensor Platform to Reduce Hospital-Acquired Infections
- First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
- Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

- Game-Changing Innovation in Surgical Instrument Sterilization Significantly Improves OR Throughput
- Next Gen ICU Bed to Help Address Complex Critical Care Needs
- Groundbreaking AI-Powered UV-C Disinfection Technology Redefines Infection Control Landscape
- Clean Hospitals Can Reduce Antibiotic Resistance, Save Lives
- Smart Hospital Beds Improve Accuracy of Medical Diagnosis
- New Fast Endoscope Drying System Improves Productivity and Traceability
- World’s First Automated Endoscope Cleaner Fights Antimicrobial Resistance
- Portable High-Capacity Digital Stretcher Scales Provide Precision Weighing for Patients in ER
- Portable Clinical Scale with Remote Indicator Allows for Flexible Patient Weighing Use
Channels
Artificial Intelligence
view channel
Privacy-Preserving AI Protects Sensitive Information in ECG Data
Artificial intelligence applied to electrocardiography can extract more than cardiac rhythm. Algorithms can infer age, sex, race, and even identity from electrocardiogram (ECG) signals, creating privacy... Read more
New AI ECG Tool Detects Early Heart Disease
Heart disease remains a leading cause of premature death, claiming almost 18 million lives each year. Early detection is crucial because timely intervention can change prognosis and conserve resources.... Read moreCritical Care
view channel
FDA-Cleared AI Wearable Monitor Detects Opioid-Related Respiratory Risk in Hospitals
Hospital patients receiving opioid therapy can develop respiratory compromise that is difficult to detect early. Continuous wearable monitoring with pattern-recognition capabilities can help clinicians... Read more
Mitral Valve Repair Device Receives EU Approval for Functional Regurgitation
Mitral regurgitation is among the most prevalent valvular heart diseases, and functional mitral regurgitation (FMR) in patients with heart failure remains challenging to manage. International guidance... Read moreSurgical Techniques
view channel
AI Tool Predicts Surgical Scheduling Gaps to Improve OR Utilization
Operating room inefficiency strains hospital capacity, inflates costs, and contributes to clinician burnout. Accurate surgical scheduling remains difficult because case duration and perioperative logistics... Read more
Innovative Central Line System Reduces Steps and Procedure Time
Central line placement is routine in critical care and surgery, yet it typically involves multiple components and numerous handoffs. Each exchange can introduce contamination risk, procedural delays, and... Read moreHealth IT
view channel
Digital Heart Model Supports Targeted Ablation in Atrial Fibrillation
Atrial fibrillation is an erratic, quivering heartbeat and a leading cause of stroke. Catheter ablation is widely used to interrupt arrhythmogenic tissue, yet many patients—especially with persistent ... Read moreAI Framework Helps Clinicians Create Trustworthy Risk Prediction Tools
Artificial intelligence (AI) is increasingly used to estimate risks for conditions such as sepsis, heart disease, and cancer, yet many models remain difficult for clinicians to interpret or trust.... Read morePoint of Care
view channel
Handheld AI Device for Point-of-Care Skin Lesion Assessment Receives CE Mark
DermaSensor (Miami, FL, USA) has received a Class IIb CE Mark for its handheld DermaSensor device, marking the start of the company’s global expansion strategy. The certification demonstrates conformity... Read more
Portable Immunoassay System Advances Toward Point-of-Care Biomarker Testing
Proxim Diagnostics Corp. (Santa Clara, CA, USA) has announced that its Profile System, a handheld point-of-care immunoassay platform, has completed development. The milestone includes completion... Read more
Portable MRI System Accelerates Emergency Brain Imaging and Triage
Emergency departments frequently face delays accessing conventional magnetic resonance imaging (MRI) for patients with suspected neurological emergencies. Such waits can slow triage, prolong boarding,... Read more







